

# Maria C Carrillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8644517/publications.pdf>

Version: 2024-02-01

66

papers

25,151

citations

126858

33

h-index

138417

58

g-index

66

all docs

66

docs citations

66

times ranked

24927

citing authors

#	ARTICLE	IF	CITATIONS
1	Working Group Recommendations for the Practice of Teleneuropsychology in Latin America. Archives of Clinical Neuropsychology, 2022, 37, 553-567.	0.3	12
2	Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic. Alzheimer's and Dementia, 2022, 18, 1067-1070.	0.4	4
3	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage, 2022, 246, 118775.	2.1	17
4	Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, 103-111.	0.4	89
5	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	4.5	54
6	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.4	64
7	The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
8	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	1.5	9
9	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	4.9	65
10	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	1.8	5
11	Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable. Alzheimer's and Dementia, 2020, 16, 814-814.	0.4	2
12	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.4	52
13	Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. Alzheimer's and Dementia, 2020, 16, 1095-1098.	0.4	0
14	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
15	AAIC Satellite Symposium explores Alzheimer's disease research in South Asia. , 2019, 15, 726-727.		0
16	Targeting Alzheimer's Disease in the Preclinical Stage. , 2019, 15, 602-603.		0
17	National Institute on Aging "Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 261-262.	0.4	7
18	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861

#	ARTICLE	IF	CITATIONS
19	Alzheimer's disease public-private partnerships: Update 2017. , 2018, 14, 522-531.		3
20	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. Alzheimer Disease and Associated Disorders, 2018, 32, 35-42.	0.6	5
21	Military-related risk factors for dementia. Alzheimer's and Dementia, 2018, 14, 1651-1662.	0.4	18
22	Combination therapy for Alzheimer's disease: Are we ready?. Alzheimer's and Dementia, 2018, 14, 1232-1233.	0.4	1
23	Lifestyle and its Potential to Preserve Cognitive Function and Reduce the Risk of Dementia. US Neurology, 2018, 14, 11.	0.2	1
24	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
25	Letter to the Editor re: Nexus of Cancer & Alzheimer's. Alzheimer's and Dementia, 2017, 13, 722-722.	0.4	1
26	Is cognitive decline measurable in preclinical Alzheimer's disease?. Alzheimer's and Dementia, 2017, 13, 322-323.	0.4	6
27	Randomized controlled trials in mild cognitive impairment. Neurology, 2017, 88, 1751-1758.	1.5	35
28	Alzheimer's disease: The next frontier”Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.4	88
29	The biomarker-based diagnosis of Alzheimer's disease. 1”ethical and societal issues. Neurobiology of Aging, 2017, 52, 132-140.	1.5	39
30	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. Alzheimer's and Dementia, 2017, 13, 267-273.	0.4	35
31	Potential roles of digital technologies in clinical trials. Alzheimer's and Dementia, 2017, 13, 1075-1076.	0.4	6
32	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
33	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 1-2.	1.2	0
34	Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. , 2016, 12, 623-630.		39
35	Tau: From research to clinical development. Alzheimer's and Dementia, 2016, 12, 1033-1039.	0.4	117
36	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.4	23

#	ARTICLE	IF	CITATIONS
37	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1031-1032.	0.4	2
38	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. <i>Alzheimer's and Dementia</i> , 2016, 12, 1186-1196.	0.4	180
39	Research priorities to reduce the global burden of dementia by 2025. <i>Lancet Neurology</i> , The, 2016, 15, 1285-1294.	4.9	284
40	The roles of inflammation and immune mechanisms in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 99-109.	1.8	161
41	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. <i>Alzheimer's and Dementia</i> , 2016, 12, 631-632.	0.4	26
42	Alzheimer's disease research in Ibero America. <i>Alzheimer's and Dementia</i> , 2016, 12, 749-754.	0.4	7
43	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
44	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.4	42
45	Round robin test on quantification of amyloid- $\beta$ 1-42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59.	0.4	46
46	CAP-advancing the evaluation of preclinical Alzheimer disease treatments. <i>Nature Reviews Neurology</i> , 2016, 12, 56-61.	4.9	80
47	How Should Cognitive Impairment Be Recognized?. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 813-814.	1.2	2
48	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
49	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
50	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 412-419.	1.2	80
51	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015, 11, 700-709.	0.4	218
52	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). <i>Alzheimer's and Dementia</i> , 2015, 11, 840-849.	0.4	10
53	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015, 11, 850-859.	0.4	43
54	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 16-24.	2.7	14

#	ARTICLE	IF	CITATIONS
55	Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A populationâ€based perspective. Alzheimer's and Dementia, 2015, 11, 718-726.	0.4	1,187
56	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 710-717.	0.4	461
57	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
58	Alzheimer's disease publicâ€private partnerships: Update 2014. Alzheimer's and Dementia, 2014, 10, 873-880.	0.4	9
59	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
60	Developing novel bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 109-114.	0.4	138
61	Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans. Alzheimer's and Dementia, 2014, 10, S105-10.	0.4	56
62	Revisiting the framework of the National Institute on Agingâ€Alzheimer's Association diagnostic criteria. Alzheimer's and Dementia, 2013, 9, 594-601.	0.4	42
63	Can we prevent Alzheimer's disease? Secondary â€preventionâ€ trials in Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 123.	0.4	100
64	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
65	Worldwide Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 337-342.	0.4	84
66	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.4	12,681